Latest news
The Debiopharm Group to initiate confirmatory phase III trial for Sanvar® in esophageal variceal bleeding
Debiopharm and TcLand sign R&D and exclusive license option for the development of sc28AT autoimmune diseases and transplantation
Debiopharm et la Haute Ecole Valaisanne collaborent pour développer les médicaments de demain
Debiopharm presents phase I monthly implant and phase II daily oral results of ZT-1 for Alzheimer´s disease
Debiopharm S.A. presented results of a double-blind placebo-controlled study on first-in-class Debio-025 in HIV-1-infected subjects
Debiopharm and Dyax Corp. restructure development agreement for Depelestat (EPI-hNE4 or DX-890) in pulmonary disorders
The Japanese Cancer Association (JCA) and Debiopharm present the inaugural 2005 JCA-Mauvernay award in Japan
Debiovision Inc., a speciality pharmaceutical developer joins the Debio companies